Barclays
NGNE icon

Barclays’s Neurogene NGNE Stock Holding History

Barclays’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-60
Closed -$3K – 7296
2018
Q2 		$3K Buy
+60
New +$15.6K ﹤0.01% 6785

Other funds holding NGNE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.6B AUM 20.91% 1-Year Est. Return

Barclays's NGNE Position: Q3 2026 in Review

Barclays increased its Neurogene (NGNE) stake by 185% in Q3 2026, buying an estimated $218K and bringing the position to 9,427 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Barclays first reported a position in NGNE in Q4 2015 and has held it in 28 quarters since. The position peaked at $861K in Q1 2022. 43 funds tracked by Wall St. Rank hold NGNE as of Q3 2026.

  • Barclays held 9,427 shares of Neurogene worth $262K as of Q3 2026.
  • Barclays bought 6,117 Neurogene shares in Q3 2026, an estimated $218K.
  • Neurogene made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3810 holding.
  • Barclays first reported a position in Neurogene in Q4 2015 and has held it in 28 quarters since.
  • Barclays's Neurogene position peaked at $861K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Neurogene as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.